Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies

• Status: Completed
• Trial end date: 2009-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is being conducted as an open-label, extended-term study for patients with chronic hepatitis B who have previously completed an Idenix-sponsored trial with telbivudine.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Telbivudine

Criteria

Inclusion Criteria:

• Patient completed a previous qualifying Idenix-Sponsored trial with telbivudine

• Patient was not discontinued from previous Idenix-Sponsored study

Other protocol-defined inclusion criteria may apply

Exclusion Criteria:

• Patient is pregnant or breastfeeding

• Patient is co-infected with hepatitis C, hepatitis D or HIV

Other protocol-defined exclusion criteria may apply